EP0486106A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Marek's disease virus vaccine
Assignee: Akzo Nobel NV
•
Filing: 1991-11-13
•
Granted: —
•
Expires: 2011-11-13
Abstract
Abstract The invention is concerned with the MD18 and MD20 polypeptides of Marek's Disease virus which can be used to vaccinate poultry against MD. The invention also relates to nucleic acid sequences encoding the MD18 or MD20 polypeptides. Said sequences can be used for the preparation of a subunit or vector vaccine.
Inventors
- 👤 Robin Wilson Morgan
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 08:59
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61P; A61P31/00; A61P31/12; A61K; A61K39/00; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16311; C12N2710/16322
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
55 words
A nucleic acid sequence encoding a MDV polypeptide characterized in that said sequence encodes at least a part of a polypeptide selected from the group consisting of: a MD18 having an amino acid sequence shown in SEQ ID NO:2 b MD20 having an amino acid sequence shown in SEQ ID NO:4 and functional equivalents thereof.
Claim 2
Dependent Claim
34 words
A nucleic acid sequence according to claim 1, characterized in that said sequence at least contains a part of the deoxyribonucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3
Claim 3
Dependent Claim
16 words
A recombinant nucleic acid molecule comprising a nucleic acid sequence according to claims 1 or 2.
Claim 4
Dependent Claim
24 words
A recombinant nucleic acid molecule according to claim 3, characterized in that the nucleic acid sequence is operably linked to an expression control sequence.
Claim 5
Dependent Claim
14 words
A vector virus containing a nucleic acid sequence according to claims 1 or 2.
Claim 6
Dependent Claim
32 words
A host cell transformed with a nucleic acid sequence according to claims 1-2 or a recombinant nucleic acid molecule according to claims 3-4 or containing a vector virus according to claim 5.
Claim 7
Dependent Claim
30 words
A polypeptide displaying MDV immunological characteristics containing at least part of the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4 or functional equivalents thereof.
Claim 8
Dependent Claim
13 words
A MDV polypeptide encoded by a nucleic acid sequence according to claims 1-2.
Claim 9
Dependent Claim
14 words
An antibody or antiserum immunoreactive with a polypeptide according to claims 7 or 8.
Claim 10
Dependent Claim
45 words
A vaccine for the protection of poultry against MDV infection, characterized in that it comprises a recombinant nucleic acid molecule according to claim 4, a vector virus according to claim 5, a host cell according to claim 6 or a polypeptide according to claims 7-8.
Claim 11
Dependent Claim
34 words
A method for preparation of MDV vaccine, characterized in that a host cell according to claim 6 is cultured, whereafter MDV containing material is collected and processed to a pharmaceutical preparation with immunizing activity.
Claim 12
Independent Claim
27 words
A method for the preparation of an MDV vaccine, characterized in that a polypeptide according to claims 7-8 is processed to a pharmaceutical preparation with immunizing activity.
Claim 13
Dependent Claim
28 words
A method for the protection of poultry against MDV infection characterized in that an effective amount of a vaccine according to claim 10 is administered to the animals.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.